JP2020535168A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535168A5
JP2020535168A5 JP2020517516A JP2020517516A JP2020535168A5 JP 2020535168 A5 JP2020535168 A5 JP 2020535168A5 JP 2020517516 A JP2020517516 A JP 2020517516A JP 2020517516 A JP2020517516 A JP 2020517516A JP 2020535168 A5 JP2020535168 A5 JP 2020535168A5
Authority
JP
Japan
Prior art keywords
phenyl
salt
production method
cancer
salt according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020517516A
Other languages
English (en)
Japanese (ja)
Other versions
JP7504791B2 (ja
JP2020535168A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052925 external-priority patent/WO2019067594A1/en
Publication of JP2020535168A publication Critical patent/JP2020535168A/ja
Publication of JP2020535168A5 publication Critical patent/JP2020535168A5/ja
Priority to JP2024014546A priority Critical patent/JP7639195B2/ja
Application granted granted Critical
Publication of JP7504791B2 publication Critical patent/JP7504791B2/ja
Priority to JP2025025024A priority patent/JP2025093936A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020517516A 2017-09-27 2018-09-26 Tam阻害剤として有用なピロロトリアジン誘導体の塩 Active JP7504791B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024014546A JP7639195B2 (ja) 2017-09-27 2024-02-02 Tam阻害剤として有用なピロロトリアジン誘導体の塩
JP2025025024A JP2025093936A (ja) 2017-09-27 2025-02-19 Tam阻害剤として有用なピロロトリアジン誘導体の塩

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762564070P 2017-09-27 2017-09-27
US62/564,070 2017-09-27
US201862714196P 2018-08-03 2018-08-03
US62/714,196 2018-08-03
PCT/US2018/052925 WO2019067594A1 (en) 2017-09-27 2018-09-26 SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024014546A Division JP7639195B2 (ja) 2017-09-27 2024-02-02 Tam阻害剤として有用なピロロトリアジン誘導体の塩

Publications (3)

Publication Number Publication Date
JP2020535168A JP2020535168A (ja) 2020-12-03
JP2020535168A5 true JP2020535168A5 (enExample) 2021-10-28
JP7504791B2 JP7504791B2 (ja) 2024-06-24

Family

ID=63794769

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020517516A Active JP7504791B2 (ja) 2017-09-27 2018-09-26 Tam阻害剤として有用なピロロトリアジン誘導体の塩
JP2024014546A Active JP7639195B2 (ja) 2017-09-27 2024-02-02 Tam阻害剤として有用なピロロトリアジン誘導体の塩
JP2025025024A Pending JP2025093936A (ja) 2017-09-27 2025-02-19 Tam阻害剤として有用なピロロトリアジン誘導体の塩

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024014546A Active JP7639195B2 (ja) 2017-09-27 2024-02-02 Tam阻害剤として有用なピロロトリアジン誘導体の塩
JP2025025024A Pending JP2025093936A (ja) 2017-09-27 2025-02-19 Tam阻害剤として有用なピロロトリアジン誘導体の塩

Country Status (35)

Country Link
US (4) US10633387B2 (enExample)
EP (2) EP3687996B1 (enExample)
JP (3) JP7504791B2 (enExample)
KR (1) KR102739325B1 (enExample)
CN (2) CN111386273B (enExample)
AU (2) AU2018342471B2 (enExample)
BR (1) BR112020006145A2 (enExample)
CA (1) CA3077308A1 (enExample)
CL (2) CL2020000791A1 (enExample)
CO (1) CO2020005009A2 (enExample)
CR (1) CR20200179A (enExample)
CY (1) CY1124952T1 (enExample)
DK (1) DK3687996T3 (enExample)
EC (1) ECSP20021655A (enExample)
ES (1) ES2904458T3 (enExample)
GE (1) GEP20227429B (enExample)
HU (1) HUE057190T2 (enExample)
IL (1) IL273579B2 (enExample)
JO (1) JOP20200081A1 (enExample)
LT (1) LT3687996T (enExample)
MA (1) MA50655B1 (enExample)
MD (1) MD3687996T2 (enExample)
MX (1) MX2020003375A (enExample)
MY (1) MY208007A (enExample)
PE (1) PE20210002A1 (enExample)
PH (1) PH12020550143A1 (enExample)
PL (1) PL3687996T3 (enExample)
PT (1) PT3687996T (enExample)
RS (1) RS62872B1 (enExample)
SA (1) SA520411638B1 (enExample)
SG (1) SG11202002821UA (enExample)
SI (1) SI3687996T1 (enExample)
SM (1) SMT202200011T1 (enExample)
TW (1) TWI821200B (enExample)
WO (1) WO2019067594A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
SI3386591T1 (sl) 2015-12-09 2020-11-30 Cadent Therapeutics, Inc. Heteroaromatski NMDA receptorski modulatorji in njihove uporabe
JP7034084B2 (ja) 2016-03-28 2022-03-11 インサイト・コーポレイション Tam阻害剤としてのピロロトリアジン化合物
ES2975336T3 (es) 2016-12-22 2024-07-04 Novartis Ag Moduladores del receptor NMDA y usos de los mismos
CA3077308A1 (en) 2017-09-27 2019-04-04 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
EA202190153A1 (ru) * 2018-06-29 2021-04-09 Инсайт Корпорейшн Составы ингибитора axl/mer
JOP20210020A1 (ar) 2018-08-03 2021-01-25 Cadent Therapeutics Inc معدلات عطرية غير متجانسة لمستقبل nmda واستخداماتها
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
AU2021230385A1 (en) * 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
JP7556604B2 (ja) * 2020-07-10 2024-09-26 範恩柯爾生物科技(中山)有限公司 トリアジン系化合物およびその組成物と用途
CN115028648B (zh) * 2021-03-03 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
US20240317692A1 (en) * 2021-07-13 2024-09-26 Nippon Soda Co., Ltd. Method for producing uracil compound

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH0395163A (ja) 1989-09-08 1991-04-19 Daicel Chem Ind Ltd 2.2.4.4.6―ペンタメチル―2.3.4.5―テトラヒドロピリミジンの製造法
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
NZ517759A (en) 1999-09-17 2004-04-30 Abbott Gmbh & Co Kinase inhibitors as therapeutic agents
ES2225624T3 (es) 2000-06-28 2005-03-16 Smithkline Beecham Plc Procedimiento de molienda por via humeda.
NZ540047A (en) 2001-04-06 2007-01-26 Wyeth Corp Use of combination consisting of rapamycin 42-ester with CCI-779, 5-fluorouracil and/or gemcitabine and optionally leucovorin and/or levofolinate for treating a neoplasm
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
AU2003272175A1 (en) 2002-10-21 2004-05-04 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
ATE399538T1 (de) 2003-03-26 2008-07-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
NZ544486A (en) 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005025515A2 (en) 2003-09-12 2005-03-24 California Institute Of Technology Proteasome pathway inhibitors and related methods
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ
AU2006316605B2 (en) * 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
KR20130141706A (ko) 2005-12-02 2013-12-26 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에 유용한 치환된 4-아미노-피롤로트리아진 유도체
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
EP1960372B1 (en) 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
ES2381212T3 (es) 2006-04-12 2012-05-24 Vertex Pharmaceuticals Incorporated 4,5-Dihidro-[1,2,4]triazolo[4,3-F]pteridinas como inhibidores de la proteincinasa PLK1 para el tratamiento de trastornos proliferativos
DK2010528T3 (en) 2006-04-19 2018-01-15 Novartis Ag 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
JP2009536161A (ja) 2006-04-25 2009-10-08 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2023926B1 (en) 2006-05-19 2011-10-12 Bayer Pharma Aktiengesellschaft Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
EP2497470B8 (en) 2006-11-22 2015-12-02 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
MX2009006345A (es) 2006-12-14 2009-06-23 Vertex Pharma Compuestos utiles como inhibidores de proteina cinasa.
JP5567837B2 (ja) 2006-12-29 2014-08-06 ライジェル ファーマシューティカルズ, インコーポレイテッド Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール
WO2008083367A2 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
NZ579811A (en) 2007-03-29 2012-02-24 Panacea Biotec Ltd Modified dosage forms of tacrolimus
CA2692028C (en) 2007-06-12 2013-06-04 Concert Pharmaceuticals, Inc. Azapeptide derivatives
AU2008287339A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−083
WO2009054864A1 (en) 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
WO2009127417A1 (en) 2008-04-16 2009-10-22 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as axl kinase inhibitors
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
CA2728729C (en) 2008-06-23 2016-09-27 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
WO2010005879A1 (en) 2008-07-09 2010-01-14 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ, インコーポレイテッド Axl阻害剤として有用な多環式ヘテロアリール置換トリアゾール
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010025073A1 (en) 2008-08-28 2010-03-04 Takeda Pharmaceutical Company Limited Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
RU2012116526A (ru) 2009-09-25 2013-10-27 Вертекс Фармасьютикалз Инкорпорейтед Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
MX354212B (es) 2010-03-10 2018-02-19 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
WO2011123493A1 (en) 2010-03-31 2011-10-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
EP2566866A1 (en) 2010-05-05 2013-03-13 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
CN103403010A (zh) 2010-10-08 2013-11-20 依兰制药公司 Polo样激酶的抑制剂
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン
ES2590778T3 (es) 2011-02-28 2016-11-23 Calitor Sciences, Llc Compuestos de quinolina sustituida
PH12013501940A1 (en) 2011-03-23 2015-12-04 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
JP6118794B2 (ja) 2011-04-01 2017-04-19 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション Axlキナーゼの阻害剤としての置換n−フェニルピリミジン−2−アミン類似体
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
PE20140570A1 (es) 2011-07-01 2014-04-28 Bayer Ip Gmbh Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
SI3513793T1 (sl) 2011-09-02 2021-07-30 Incyte Holdings Corporation Heterociklilamini kot zaviralci PI3K
EP2758052B9 (en) 2011-09-18 2019-03-27 Euro-Celtique S.A. Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
US9273056B2 (en) 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
EP3045453A1 (en) 2011-11-14 2016-07-20 Cephalon, Inc. Uracil derivatives as axl and c-met kinase inhibitors
KR101892330B1 (ko) 2011-11-29 2018-08-27 페로스피어 파마슈티컬스 인코포레이티드 항응혈 역전 물질들
US8993756B2 (en) 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
DK2810937T3 (en) 2012-01-31 2017-03-13 Daiichi Sankyo Co Ltd PYRIDONE DERIVATIVES
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
WO2013162061A1 (ja) 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2014039714A2 (en) 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR20150061651A (ko) 2012-09-26 2015-06-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ire1의 조절
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
BR112015009942A2 (pt) 2012-11-01 2017-07-11 Incyte Corp derivados de tiofeno fundidos tricíclicos como inibidores de jak
CN104936963B (zh) 2012-11-20 2017-11-28 普罗齐纳斯有限公司 作为蛋白激酶抑制剂的硫醚衍生物
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
WO2014164729A1 (en) 2013-03-12 2014-10-09 Arqule, Inc. Substituted tricyclic pyrazolo-pyrimidine compounds
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
JP6493218B2 (ja) 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
WO2015081783A1 (zh) 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
EP3102579B1 (en) 2014-02-03 2019-04-10 Cadila Healthcare Limited Heterocyclic compounds
GB201420285D0 (en) 2014-11-14 2014-12-31 Bergenbio As Process
ES2746839T3 (es) 2014-12-18 2020-03-09 Pfizer Derivados de pirimidina y triazina y su uso como inhibidores de AXL
WO2016183071A1 (en) * 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
SMT202100527T1 (it) 2015-07-30 2021-11-12 Macrogenics Inc Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
US20180296561A1 (en) 2015-10-07 2018-10-18 The University Of North Carolina At Chapel Hill The Methods For Treatment Of Tumors
BR122021026497B1 (pt) 2015-10-13 2022-10-25 Nihon Nohyaku Co., Ltd Heterocíclico condensado contendo grupo oxima ou sal deste, inseticida agrícola e hortícola, método para usar o inseticida e agente de controle de ectoparasitas animais
JP6921818B2 (ja) 2015-11-14 2021-08-18 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. 置換キノリン化合物の結晶形およびその医薬組成物
US9695150B2 (en) 2015-11-14 2017-07-04 Calitor Sciences, Llc Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
JP7034084B2 (ja) 2016-03-28 2022-03-11 インサイト・コーポレイション Tam阻害剤としてのピロロトリアジン化合物
SG10202010414QA (en) 2016-04-22 2020-11-27 Incyte Corp Formulations of an lsd1 inhibitor
TW201803871A (zh) * 2016-06-24 2018-02-01 英塞特公司 作為PI3K-γ抑制劑之雜環化合物
EP4206213A1 (en) 2016-07-15 2023-07-05 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of smn2
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
CA3077308A1 (en) 2017-09-27 2019-04-04 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
EA202190153A1 (ru) 2018-06-29 2021-04-09 Инсайт Корпорейшн Составы ингибитора axl/mer
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors

Similar Documents

Publication Publication Date Title
JP2020535168A5 (enExample)
AU2013203283B2 (en) Processes for the preparation of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine
KR102128127B1 (ko) 5-(2,6-디-4-모르폴리닐-4-피리미디닐)-4-트리플루오로메틸피리딘-2-아민의 개선된 제조 방법
JP2007521340A5 (enExample)
HUE029616T2 (en) New phosphate derivatives, process for their preparation and pharmaceutical compositions containing them
WO2000017163A1 (en) Cyanophenyl derivatives
CA2971872A1 (en) Mutant idh1 inhibitors useful for treating cancer
CN107176955B (zh) 一种巴瑞替尼的制备方法
JP2010539237A5 (enExample)
KR20160095161A (ko) 포스파티딜이노시톨 3-키나제 억제제의 가공 방법
JP7749857B2 (ja) キナゾリン化合物を合成するための方法
JP2018532713A5 (enExample)
US20200048264A1 (en) Processes for the Preparation of Acalabrutinib and Intermediates Thereof
AU2024201119A1 (en) Methods of preparing cytotoxic benzodiazepine derivatives
WO2014024950A1 (ja) 1,4-ベンゾオキサジン化合物の製法
CN112955449B (zh) 制备bet溴结构域抑制剂的固体形式的方法
CN101921260B (zh) 一种伊马替尼的制备方法
TWI833800B (zh) 用於製造3-[(1S)-1-咪唑并[1,2-a]吡啶-6-基乙基]-5-(1-甲基吡唑-4-基)三唑并[4,5-b]吡嗪的改進方法及其多晶型形式
KR20130056887A (ko) 시클로펜타퀴나졸린의 합성
WO2016139773A1 (ja) シロドシン合成中間体の新規合成方法
EP3773584A1 (en) Methods for preparing substituted pyridinone-containing tricyclic compounds
JP7658916B2 (ja) Btk阻害剤を調製するためのプロセス及び中間体
TH2001001805A (th) เกลือของอนุพันธ์ไพร์โรโลไตรอะซินที่ใช้ประโยชน์เป็นสารยับยั้ง tam
HU230805B1 (hu) Eljárás és köztitermék baricitinib előállítására
CN109535060B (zh) 一种刺猬通路抑制剂及其制备方法和应用